Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Covington
Accenture
Healthtrust
McKesson
Medtronic

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,236,285

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,236,285 protect, and when does it expire?

Patent 8,236,285 protects ZOLPIMIST and is included in one NDA.

This patent has eighty-eight patent family members in ten countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 8,236,285
Title:Buccal, polar and non-polar spray containing zolpidem
Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.
Inventor(s): Dugger, III; Harry A. (Flemington, NJ), Abd El-Shafy; Mohammed (Hauppauge, NY)
Assignee: Novadel Pharma Inc. (Flemington, NJ)
Application Number:12/576,457
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,236,285

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aytu ZOLPIMIST zolpidem tartrate SPRAY, METERED;ORAL 022196-001 Dec 19, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF TRANSIENT INSOMNIA ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Baxter
Argus Health
AstraZeneca
Merck
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.